Head-to-head evidence
HSK41959 vs IDE397
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MAT2A · full Non-Small Cell Lung Cancer pipeline
HSK41959
Developed by Haisco Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2029 · NCT07699757 (registry estimate)
IDE397
Developed by IDEAYA Biosciences
NCT05975073 · Phase 1/2 · completed
The study is a nonrandomized, open-label, single-arm dose-exploration and dose-expansion trial without a placebo or active comparator. Its Part 2 primary outcome is objective tumor response by RECIST 1.1, but no results are posted, so whether the primary endpoint was met cannot be determined.
Next expected readout: April 2028 · NCT07277413 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HSK41959's landscape · IDE397's landscape